GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of FLOW got published and nobody in here is talking about eGFR slope — 25 comments in the full submission. View in context.
287
c/trialwatch·submitted 3 days ago by u/ines_castellanos

FLOW got published and nobody in here is talking about eGFR slope

Paperbranch of 7 comments

The title is the argument: FLOW got published and nobody in here is talking about eGFR slope. Here is the rest of it. Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are…

Read the full submission and all 25 comments →

This branch

7 comments, started 2 days ago
u/ines_castellanos0 points·2 days ago

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

replysharereportpermalink
u/aurel_mwangi1 point·2 days ago

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

replysharereportpermalink
u/cloudy_vial_carol1 point·2 days ago

discontinuation rate is a result, not a footnote

replysharereportpermalink
u/whois_wanda1 point·1 days ago

the confidence interval is the finding, the point estimate is the headline

replysharereportpermalink
u/hamza_zielinski1 point·1 days ago

FLOW was kidney outcomes and it is the one nobody quotes

replysharereportpermalink
u/adaeze_weiss1 point·2 days ago·edited

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

replysharereportpermalink
u/rina_bergstrom1 point·2 days ago

Careful with that mean.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →